Print
Email
Print Edition StoriesMonday, March 30, 2009
BioVex raises $40M in series F funding
By Mass High Tech staff
MHT's Marc Songini: RI plans launch of cord blood center
Innerscope Research sensor vest tests biometric response to visual aids
MHT managing editor Rodney Brown on NECN: 22 tech companies give back to community
BioVex Inc., a Woburn-based developer of cancer and infectious disease drugs and vaccines, has pulled in $40 million in its first close on a series F funding round.
Forbion Capital Partners led the financing, with supporting investment from Credit Agricole Private Equity, Harris & Harris Group, Innoven Partners, New Science Ventures, Triathlon Medical Venture Partners and Scottish Equity Partners.
The company is planning to raise an additional $20 million to prepare a BLA filing for its OncoVEX GM-CSF, a metastatic melanoma product that just completed a Phase 2 study and is preparing for a Phase 3 study, BioVex president and CEO Philip Astley-Sparke said in a statement.
For the Phase 3 study, which will begin in the second quarter of 2009, about 360 patients are expected to participate, with 240 receiving the OncoVEX GM-CSF and 120 patients receiving the control.
Privately-held BioVex last reported closing a $35 million Series E round of funding in November 2007. The proceeds, the company said, would fund Phase 3 clinical trials of its lead melanoma drug as well as trials for its treatments for head and neck, and pancreatic cancers. By Mass High Tech reported accounts, this latest round brings BioVex’s total private financing raised to more than $130 million.
BioVex maintains its research and development facility in Oxford, England.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
